Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in…
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA…
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of…
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June…
Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)CAMBRIDGE, Mass., June 04, 2025 (GLOBE…
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS)…
Collaboration will leverage Rosy Wellness’ extensive reach and community of over 250,000 women Rosy Wellness is a multi-award winning app…
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to…
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically…
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval,…